Alliancebernstein L.P. Cel Sci Corp Transaction History

Alliancebernstein L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $66,822 - $129,241	-25,900 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.93 - $7.7 $31,440 - $61,600	-8,000 Reduced 23.6%	25,900 $102,000
Q2 2021 Jul 30, 2021	BUY	$8.68 - $27.49 $70,308 - $222,669	8,100 Added 31.4%	33,900 $294,000
Q1 2021 May 06, 2021	SELL	$12.0 - $27.64 $104,400 - $240,468	-8,700 Reduced 25.22%	25,800 $392,000
Q4 2020 Feb 08, 2021	SELL	$11.05 - $16.62 $51,935 - $78,114	-4,700 Reduced 11.99%	34,500 $402,000
Q1 2020 May 14, 2020	BUY	$7.54 - $17.05 $69,368 - $156,860	9,200 Added 30.67%	39,200 $452,000
Q3 2019 Nov 14, 2019	SELL	$6.0 - $9.6 $1,800 - $2,880	-300 Reduced 0.99%	30,000 $268,000
Q2 2019 Aug 14, 2019	BUY	$3.77 - $8.67 $114,231 - $262,701	30,300 New	30,300 $254,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.